Eli Lilly Signs $2.7 Billion Licensing Deal with AI Drug Developer
Eli Lilly has signed a licensing agreement worth $2.7 billion (approximately 4 trillion won) with a drug development company that leverages artificial intelligence (AI). This deal is seen as an example that highlights the growing demand for AI-driven drug development in the global pharmaceutical industry.
On March 29 (local time), Insilico Medicine, a drug development company listed in Hong Kong, announced that it has entered into a licensing and research agreement with Eli Lilly worth up to $2.75 billion.
Insilico Medicine will receive $115 million (approximately 168 billion won) as an upfront payment. The remaining amount will be paid in stages, depending on regulatory and commercial milestones. Eli Lilly has secured exclusive rights to develop, manufacture, and commercialize certain preclinical oral drug candidates discovered using Insilico's AI engine.
Insilico Medicine is a clinical-stage biotech company that utilizes generative AI and automation. The company went public on the Hong Kong Stock Exchange in December 2025.
This deal reflects the pharmaceutical industry's trend toward expanding the use of AI. In January this year, Eli Lilly announced the establishment of an "AI Collaborative Innovation Lab" in San Francisco with Nvidia and revealed plans to invest up to $1 billion over the next five years.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Additionally, last year, Eli Lilly signed a $345 million agreement with Alux, a subsidiary of China's XtalPi. At a conference, Lucas Montars, Eli Lilly's Chief Financial Officer (CFO), stated that the company is "making large-scale investments" in AI for research and development (R&D).
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.